Molecular profiling has enabled the identification of biologically distinct MCL subtypes, such as the indolent SOX11‐negative variant and the more aggressive blastoid and pleomorphic variants, the latter being associated with poorer clinical outcomes [5]. This evidence concerns the gene SOX11 and mantle cell lymphoma.